Current Rating and Its Significance
MarketsMOJO’s current Sell rating on Piramal Pharma Ltd indicates a cautious stance towards the stock, suggesting that investors should consider reducing exposure or avoiding new purchases at this time. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. The rating was revised on 30 July 2026, reflecting a significant change in the company’s outlook, but the detailed assessment below uses the latest data available as of 10 September 2026.
Quality Assessment
As of 10 September 2026, Piramal Pharma’s quality grade is assessed as below average. The company has demonstrated weak long-term fundamental strength, with a compounded annual growth rate (CAGR) of operating profits declining by -9.27% over the past five years. This negative growth trend highlights challenges in sustaining profitability and operational efficiency. Additionally, the company’s ability to service debt remains limited, with a high Debt to EBITDA ratio of 6.16 times, signalling elevated financial risk. The average Return on Equity (ROE) stands at a mere 0.58%, indicating low profitability generated per unit of shareholders’ funds. These factors collectively weigh on the company’s quality score and contribute to the cautious rating.
Valuation Considerations
Currently, Piramal Pharma is considered expensive relative to its capital employed. The stock trades at an Enterprise Value to Capital Employed (EV/CE) ratio of 2.7, which is high given the company’s subdued returns. Its Return on Capital Employed (ROCE) is notably low at 0.7%, reflecting limited efficiency in generating profits from its capital base. Despite this, the stock is trading at a discount compared to its peers’ average historical valuations, which may offer some valuation cushion. However, the expensive valuation relative to its current profitability metrics justifies the conservative stance.
Financial Trend and Profitability
The latest financial data as of 10 September 2026 reveals a challenging trend for Piramal Pharma. The company reported negative results in the quarter ending June 2026, with Profit Before Tax excluding Other Income (PBT LESS OI) at a loss of ₹96.87 crores, representing a decline of -100.5% compared to the previous four-quarter average. The half-yearly ROCE is at a low 2.61%, while the debt-equity ratio has increased to 0.70 times, the highest in recent periods, indicating rising leverage. Over the past year, the stock has delivered a modest return of 9.39%, but profits have fallen sharply by -225.1%, underscoring the disconnect between market performance and underlying earnings deterioration. These financial trends highlight the risks associated with the company’s current trajectory.
Technical Outlook
From a technical perspective, Piramal Pharma exhibits a bullish grade, reflecting positive price momentum and recent gains. The stock has shown resilience with a 3-month return of +32.42% and a 6-month return of +40.13%, indicating strong short- to medium-term price appreciation. Year-to-date, the stock is up 26.47%, and over the past month, it has gained 1.99%. Despite this positive technical momentum, the fundamental weaknesses and valuation concerns temper enthusiasm, leading to the overall Sell rating.
Stock Performance Summary
As of 10 September 2026, Piramal Pharma’s stock price movement reflects mixed signals. While short-term technical indicators are encouraging, the company’s fundamental and financial challenges remain significant. The stock’s one-day change was a slight decline of -0.09%, and its one-week gain stands at +1.61%. Over the longer term, the stock’s 1-year return of 9.39% is modest, especially when juxtaposed with the steep decline in profitability. Investors should weigh these factors carefully when considering their position in the stock.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
What This Rating Means for Investors
The Sell rating on Piramal Pharma Ltd signals that the stock currently carries elevated risks due to weak fundamentals, expensive valuation, and deteriorating financial trends, despite positive technical momentum. Investors are advised to approach the stock with caution, considering the company’s limited profitability growth, high leverage, and recent negative earnings performance. While the stock’s price has shown resilience, the underlying business challenges suggest that the risk-reward balance is unfavourable at present.
Investor Considerations and Outlook
For investors, the key takeaway is to prioritise companies with stronger fundamental profiles and more attractive valuations, especially in the Pharmaceuticals & Biotechnology sector where competition and innovation drive long-term success. Piramal Pharma’s current metrics indicate that it is struggling to generate sustainable returns on capital and manage its debt effectively. Until there is a clear improvement in operating profits, debt servicing capacity, and return ratios, the stock is likely to remain under pressure.
Monitoring future quarterly results and any strategic initiatives by the company will be essential to reassess its outlook. Meanwhile, the technical strength may offer short-term trading opportunities, but these should be balanced against the broader fundamental risks.
Summary of Key Metrics as of 10 September 2026
- Mojo Score: 37.0 (Sell Grade)
- Operating Profit CAGR (5 years): -9.27%
- Debt to EBITDA Ratio: 6.16 times
- Return on Equity (avg): 0.58%
- PBT LESS OI (Q2 Jun 26): -₹96.87 crores (-100.5%)
- ROCE (Half Year): 2.61%
- Debt-Equity Ratio (Half Year): 0.70 times
- Enterprise Value to Capital Employed: 2.7
- Stock Returns: 1Y +9.39%, 6M +40.13%, 3M +32.42%
In conclusion, while Piramal Pharma Ltd’s stock price has demonstrated some positive momentum recently, the company’s fundamental and financial challenges justify the current Sell rating by MarketsMOJO. Investors should carefully evaluate these factors in the context of their portfolio strategy and risk tolerance.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
